Announcement Announcement
The Intractable and Rare Diseases Task Force of the Pharmaceutical Industrial Policy Committee of the Japan Pharmaceutical Manufacturers Association (hereinafter referred to as the JPMA) has published “Recommendations on Intractable and Rare Diseases ” aimed at addressing the challenges faced by patients with intractable and rare diseases and their families.
Based on these recommendations, we have engaged in active dialogue with stakeholders from various sectors—including patient organizations, pharmaceutical companies, government agencies, medical institutions, and academia—and have been working to realize the recommendations’ goals, such as “creating an environment where patients and their families can easily access necessary information,” “promoting societal understanding of rare diseases,” and “accelerating the development of treatments.”
Therefore, with the goal of creating a clinical trial website that is easily accessible and searchable for patients with intractable and rare diseases and their families, we have been collaborating with the National Institute of Health and Nutrition,Health and Nutrition Institute and the research team under the Ministry of Health, Labor and Welfare’s Intractable Diseases Policy Research Project—“Strategic Integrated Research to Promote Research and Improve Medical Care for Overcoming Intractable Diseases”—has now been launched.
Intractable Diseases Clinical Trials Web: https://nanbyo-chiken.nibn.go.jp/
We expect that as more patients utilize the “Intractable Diseases Clinical Trials Web,” it will become easier for them to participate in clinical trials. This will enable more patient-centered development than ever before, thereby contributing to the development of therapeutic drugs. JPMA will continue its efforts to address the challenges faced by patients with intractable and rare diseases and their families.
Intractable Diseases Clinical Trials Web: https://nanbyo-chiken.nibn.go.jp/
We expect that as more patients utilize the “Intractable Diseases Clinical Trials Web,” it will become easier for them to participate in clinical trials. This will enable more patient-centered development than ever before, thereby contributing to the development of therapeutic drugs. JPMA will continue its efforts to address the challenges faced by patients with intractable and rare diseases and their families.